skip to main content


Jul 24, 2017

Idenix Pharmaceuticals, Inc. v. Gilead Pharmasset al.

We successfully represented Gilead in a patent case relating to antiviral compounds for use in the treatment of Hepatitis C. Gilead proved that Idenix’s patent was invalid for insufficiency and inutility, and that its own patent was not anticipated or otherwise invalid. 


  • Patents

© 2015 Belmore Neidrauer LLP | Legal Disclaimer | Privacy Policy